Skip to main content
. 2020 Jul 21;2020(7):CD009833. doi: 10.1002/14651858.CD009833.pub2

2. Summary of included studies.

Characteristic n Percentage
Underlying condition    
Cancer
HIV/AIDS
ICU
Mixed at‐risk
Organ transplant
23
1
16
7
2
46.9%
2.0%
32.7%
14.3%
4.1%
Age of patients    
Adult
Neonate
Pediatric
Mixed
Unknown
26
3
3
5
12
53.1%
6.1%
6.1%
10.2%
24.5%
Study design    
Prospective consecutive
Retrospective consecutive
Retrospective case‐control
26
12
11
53.1%
24.5%
22.4%
Fungal type    
Aspergillus only
Candida only
PJP only
Mixed fungal types
12
10
3
24
24.5%
20.4%
6.1%
49.0%
Test brand    
Fungitell
Glucatell
Fungitec‐G
Wako
Dynamiker Fungus
36
5
3
3
2
73.5%
10.2%
6.1%
6.1%
4.1%
Sampling strategy    
Single sample
Multiple samples
Unknown
20
26
3
40.8%
53.1%
6.1%
Reference standard used    
EORTC
Proven Candida
PJP microscopy/PCR
Study‐specific
36
8
3
2
73.5%
16.3%
6.1%
4.1%
Low risk of bias    
Participant selection
Index test
Reference standard
Flow and timing
35
49
41
41
71.4%
100.0%
83.7%
83.7%

EORTC: European Organization for Research and Treatment of Cancer; ICU: intensive care unit; PCR: polymerase chain reaction; PJP: Pneumocystis jirovecii pneumonia.